Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180 | Director | May 20, 2020 | May 22, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eloxx Pharmaceuticals, Inc.
Report date May 20, 2020 · Filed May 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.39 · Expires 2030-05-20 | Direct | 20,000 |
Reported balance
After 2020-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-20 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2020 Filed May 22, 2020 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001415889-20-001300 · form4-05222020_040510.xml · derivative · entry 1 Noiman Silvia · CIK 0001340877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| May 29, 2019 Filed May 29, 2019 21:22 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-19-000627 · form4-05292019_020533.xml · derivative · entry 1 Noiman Silvia · CIK 0001340877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-29 F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on May 29, 2020 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 22:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $23.27 | $0.00 |
DisclosureSEC source: 0001209191-18-038658 · doc4.xml · derivative · entry 3 Noiman Silvia · CIK 0001340877 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-06-15 F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 22:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantEmployee Stock Option (Right to Buy) · Derivative | 141,389 | $0.00 Strike: $23.27 | $0.00 |
DisclosureSEC source: 0001209191-18-038658 · doc4.xml · derivative · entry 2 Noiman Silvia · CIK 0001340877 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,389 Underlying: Common Stock · 141,389 shares Expires 2028-06-15 Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 22:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantCommon Stock | 141,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038658 · doc4.xml · nonDerivative · entry 1 Noiman Silvia · CIK 0001340877 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,389 Read SEC document |
| June 06, 2018 Filed Jun 29, 2018 20:12 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionStock Option (Right to Buy) · Derivative | 349,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-040022 · doc4.xml · derivative · entry 2 Noiman Silvia · CIK 0001340877 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 349,400 shares Expires 2024-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The option was issued pursuant to the Company's Eloxx Pharmaceuticals Ltd. Share Ownership and Option Plan (2013) and was priced at Israeli New Shekel 0.0020. This amount reflects the U.S. dollar equivalent of the exercise price as of the transaction date using an exchange rate of 1:3.5736, as reported by Bloomberg. F3 · derivative.exercise_date: The option was fully vested and exercisable as of October 26, 2016. Read SEC document |
| June 06, 2018 Filed Jun 29, 2018 20:12 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 349,400 | $0.00 | $209.64 |
DisclosureSEC source: 0001209191-18-040022 · doc4.xml · nonDerivative · entry 1 Noiman Silvia · CIK 0001340877 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 490,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The option was issued pursuant to the Company's Eloxx Pharmaceuticals Ltd. Share Ownership and Option Plan (2013) and was priced at Israeli New Shekel 0.0020. This amount reflects the U.S. dollar equivalent of the exercise price as of the transaction date using an exchange rate of 1:3.5736, as reported by Bloomberg. F2 · balance_after: Represents the total number of shares owned by the Reporting Person as of the date of filing. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.